Zhejiang East Asia Pharmaceutical Co. Ltd.

East Asia Pharmaceutical released its 2026 interim report, with total operating revenue of 466 million yuan and net profit attributable to the parent company of minus 118 million yuan, a decrease of 88.1487 million yuan compared with the same period last year, widening the loss. Net cash inflow from operating activities was 51.814 million yuan, the asset-liability ratio was 44.48 percent, and the gross margin was 23.88 percent, down 6.27 percentage points year on year. Return on equity was minus 6.95 percent, down 5.32 percentage points year on year. Diluted earnings per share were minus 1.03 yuan, a decrease of 0.77 yuan year on year. The number of shareholders was 10,400, and the top ten shareholders held 56.90 percent of the total share capital.

East Asia Pharmaceutical released its 2026 interim report. First-half operating revenue was 466 million yuan, up 12.1 percent year on year, but net profit attributable to the parent swung from a loss of 30.23 million yuan in the same period last year to a loss of 118 million yuan. Net profit attributable to the parent after deducting non-recurring items widened from a loss of 35.88 million yuan to a loss of 124 million yuan. In the second quarter, operating revenue was 202 million yuan, down 10.4 percent year on year, with a net loss attributable to the parent of 83.18 million yuan and a net loss after deducting non-recurring items of 84.9 million yuan. As of the end of the second quarter, total assets were 3.068 billion yuan, down 8.1 percent from the end of the previous year, and net assets attributable to the parent were 1.703 billion yuan, down 5.7 percent. The company focuses on chemical active pharmaceutical ingredients, pharmaceutical intermediates and chemical preparations. During the reporting period, it actively advanced the commercialisation of preparation products, obtained multiple preparation approvals, and increased research and development investment.